Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.

Expert review of clinical pharmacology - 1 Oct 2021

Repetto Matteo, Crimini Edoardo, Giugliano Federica, Morganti Stefania, Belli Carmen, Curigliano Giuseppe

Abstract excerpt

Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a pathway characterized by recurring alterations in cancer. Its dysregulations enhance cancer cell proliferation, survival, migration and invasion, as well as angiogenesis and immune evasion.Areas covered: FGFR/FGF selective inhibitors belong to a broad class of drugs with some being approved for specific indications and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Fibroblast Growth Factors

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasms

Share to Receptors, Fibroblast Growth Factor

Share to Signal Transduction

Source

Identifiers

PMID: 34591728
DOI: 10.1080/17512433.2021.1947246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.PMID 34591728Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

Molecular Targeting of the Fibroblast Growth Factor Receptor (FGFR) Pathway Across Various CancersSemantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.Semantic proximity Read ↗

FGFR families: biological functions and therapeutic interventions in tumorsSemantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in CancerSemantic proximity Read ↗

Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.Semantic proximity Read ↗

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read ↗

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.Semantic proximity Read ↗

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.Semantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.